LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Home・Stock List・Abeona Therapeutics Inc

Abeona Therapeutics Inc

Closed

6.81 1.64

Buy Sell

Overview

Share price change

24h

Current

Min

6.6

Max

6.84

Key metrics
By Trading Economics
P/E Sector Avg	10.182 35.733
Employees	136

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+198.51% upside

Dividends
By Dow Jones
Next Earnings	12 Nov 2025

Market Stats
By TradingEconomics
Market Cap	11M 287M
Previous open	5.17
Previous close	6.81

Abeona Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

9 Sept 2025, 23:37 UTC

Hot Stocks

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 Sept 2025, 20:41 UTC

Earnings

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 Sept 2025, 20:30 UTC

Earnings

GameStop 2Q Sales, Profit Rise

9 Sept 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 Sept 2025, 21:35 UTC

Earnings

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 21:32 UTC

Earnings

Oracle's Backlog Swells With Big Customer Deals -- Update

9 Sept 2025, 21:02 UTC

Acquisitions, Mergers, Takeovers

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Sept 2025, 20:33 UTC

Earnings

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 Sept 2025, 20:26 UTC

Earnings

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 20:23 UTC

Earnings

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 20:12 UTC

Earnings

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 Sept 2025, 20:10 UTC

Earnings

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 Sept 2025, 20:10 UTC

Earnings

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 Sept 2025, 20:09 UTC

Earnings

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 Sept 2025, 20:09 UTC

Earnings

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 Sept 2025, 20:08 UTC

Earnings

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 Sept 2025, 20:07 UTC

Earnings

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 Sept 2025, 20:06 UTC

Earnings

Oracle 1Q Software Revenue $5.72B >ORCL

9 Sept 2025, 20:06 UTC

Earnings

Synopsys 3Q Adj EPS $3.39 >SNPS

9 Sept 2025, 20:06 UTC

Earnings

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Rev $14.93B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q EPS $1.01 >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Synopsys 3Q EPS $1.50 >SNPS

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Services Revenue $1.35B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Adj EPS $1.47 >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Hardware Revenue $670M >ORCL

Peer Comparison

Price change

Abeona Therapeutics Inc Forecast

Price Target

By TipRanks

198.51% upside

12 Months Forecast

Average 20 USD 198.51%

High 20 USD

Low 20 USD

Based on 2 Wall Street analysts offering 12 month price targets forAbeona Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Abeona Therapeutics Inc - Dist in the past 3 months.

Financials

About Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.